Login to Your Account

Inotek Vision for Glaucoma Supported by $21M in Financing

By Catherine Shaffer
Staff Writer

Friday, September 27, 2013

Inotek Pharmaceuticals Corp., of Lexington, Mass., plans to apply $21 million in proceeds from a venture financing, including $7 million in venture debt financing, to advance its A1 subtype adenosine mimetic for glaucoma and ocular hypertension. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription